Trial Profile

A Phase II Study of Enzalutamide Plus Dutasteride/Finasteride as First Line Treatment for Vulnerable Patients ≥ 65 Years With Systemic Prostate Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dutasteride (Primary) ; Enzalutamide (Primary) ; Finasteride (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use

Most Recent Events

04 Jun 2024 Results assessing safety and efficacy of enzalutamide (Enz) with 5-alpha reductase inhibitors as an androgen deprivation therapy sparing approach for older men with castration-sensitive prostate cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
28 Dec 2023 Status changed from active, no longer recruiting to completed.
13 Jul 2023 Planned End Date changed from 1 Sep 2024 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com